The complexity of adenosine signaling contributed at least partially to the debilitating side effects and suspension of the clinical phase III trial of the A2AR antagonist tozadenant for PD, which resulted in the death of five patients due to inflammatory complications. This evidence concerns the gene ADORA2A and Parkinson disease.